Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure

Eur J Prev Cardiol. 2021 Aug 9;28(9):e28-e31. doi: 10.1177/2047487320912375.

Authors

Andrea Salzano¹, Muhammad Zubair Israr², Daniel Fernandez Garcia³, Laura Middleton³, Roberta D'Assante⁴, Alberto M Marra^{4

5}, Michele Arcopinto⁴, Yoshiyuki Yazaki², Dennis Bernieh², Shabana Cassambai², Karen Page³, Giuseppe Rengo^{4

6}, Eduardo Bossone⁷, Antonio Cittadini⁴, Jacqueline A Shaw³, Toru Suzuki²

Affiliations

¹ IRCCS SDN, Diagnostic and Nuclear Research Institute, Italy.
² Department of Cardiovascular Sciences, University of Leicester, UK.
³ Leicester Cancer Research Centre, University of Leicester, UK.
⁴ Department of Translational Medical Sciences, Federico II University, Italy.
⁵ Center for Pulmonary Hypertension, Heidelberg University Hospital, Germany.
⁶ Istituti Clinici Scientifici Maugeri SpA Società Benefit, Italy.
⁷ Division of Cardiology, AORN Cardarelli, Italy.

PMID: 32212838
DOI: 10.1177/2047487320912375

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell-Free Nucleic Acids*
Heart Failure* / diagnosis
Humans
Liquid Biopsy

Substances

Cell-Free Nucleic Acids